Eosinophilic esophagitis (EOE), also known as allergic esophagitis, is a chronic, allergen-driven immune-mediated esophageal disease. The disease is caused by the accumulation of eosinophils in the mucosal tissue of the esophagus. It is first seen in children but can also occur in adults. Symptoms include dysphagia, food impact, vomiting, and heartburn, which may cause damage to the esophagus, fibrosis, and dysfunction. At present, the cause of EOE is not yet clear, but it involves a complex interaction of genes, environmental factors, and immune system dysfunction.
There is currently no effective treatment for this disease, but steroid treatment can improve the symptoms of this disease. Patients mainly use two drugs, budesonide and fluticasone. Topical budesonide has a good effect on eosinophilic esophagitis, which can be used in two ways: liquid nebulizer and dry powder inhaler. Fluticasone is mainly used to treat symptoms related to excessive immune response caused by various diseases, such as allergies and asthma. Generally speaking, this medicine is well tolerated, which main side effects may include hoarse voice or sore throat, and esophageal yeast infection. Budesonide is powerful with a broad market. In 2020, it occupies 56.58% of the global eosinophilic esophagitis drug market.
Eosinophilic esophagitis drugs are commonly found in hospitals, clinics, and pharmacies. A hospital is an institution that conducts health examinations, disease prevention, treatment, and care of patients. Due to the high incidence of eosinophilic esophagitis in children, many hospitals for children have also opened related programs. A clinic is a kind of sanitation facility, which can be privately operated, or it can be managed and funded by the government. Some large clinics have set up special departments to diagnose and treat eosinophilic esophagitis, and provide children with pediatric gastroenterologists. Pharmacies refer to drug retail stores, where staff are increasingly providing treatment, consultation and advice to patients with eosinophilic gastrointestinal diseases. In general, hospitals account for more than half of the market application of eosinophilic esophagitis drugs. It is estimated that its value will reach US$133.07 million by 2026, with a compound annual growth rate of 7.87% from 2020 to 2026.
Prospect Analysis of Eosinophilic Esophagitis Drug Industry in Various Regions
North America is the largest revenue market, with a market share of 42.33% in 2015 and 42.78% in 2019, an increase of 0.45%. Europe ranks second with a market share of 40.36%.
Get the Complete Sample, Please Click: https://www.globalmarketmonitor.com/reports/762647-eosinophilic-esophagitis-drug-market-report.html
Since the development of the global eosinophilic esophagitis pharmaceutical industry, its market concentration has reached a high level. In terms of revenue from eosinophilic esophagitis drugs in 2019, the top five manufacturers accounted for up to 78.95% of the market share. Most of the companies in the industry are concentrated in Europe and the United States. The top three companies are AstraZeneca, GlaxoSmithKline and Bayer, with revenue market shares of 32.96%, 19.49% and 11.18% in 2019.
Europe, the United States and other places have developed economies, with a high standard of living and a strong sense of health. Therefore, its eosinophilic esophagitis drugs developed early. In addition, with capital, talent and technological advantages, these developed regions are increasing the research and development of eosinophilic esophagitis drugs. It is expected that their market will further expand, intensifying the existing competitive landscape.
Although in 2019, the Asia-Pacific, Latin America, the Middle East and Africa only accounted for 11.76%, 4.76% and 1.48% of the global eosinophilic esophagitis drug market, in recent years, emerging countries in the Asia-Pacific region dominated by China and India have developed with the strong speed, which has brought opportunities to the EOE market. The Asia-Pacific has great market potential and is expected to become the fastest growing region in the eosinophilic esophagitis drug industry in the future.
Increasing the R&D of Eosinophilic Esophagitis Drugs Has Become a Development Trend
According to the research, the total output value of the global eosinophilic esophagitis drug market in 2015 was US$117.42 million. By 2020, its market size will increase to US$157.1 million. We predict that by 2026, the global market value of eosinophilic esophagitis drugs can reach US$251.2 million. The compound annual growth rate for 2019-2026 is 8.07%.
From the late 1960s to the 1970s, the first suspected case of eosinophilic esophagitis was reported. But until now, we still do not know the pathogenesis of the disease. In recent years, environmental degradation has caused an increase in allergens in the air, so the prevalence and incidence of eosinophilic esophagitis have increased rapidly. It is estimated that the current prevalence in North America and Europe is 1 to 6 per 10,000 people. Therefore, the EOE drug market has great potential. With the introduction of the policy to encourage the R&D of rare disease drugs, pharmaceutical companies have increased their investment in rare diseases, so the industry market will further expand.
With the development of medical technology, pharma giants has invested more in R&D and some pharmaceutical companies have achieved some clinical success. The rapid development of the biopharmaceutical industry, especially the development of monoclonal antibody technology, has brought more opportunities and development to the eosinophilic esophagitis drug market, and more effective drugs may appear in the future. Therefore, companies in this industry should focus on their own products, continue to increase R&D investment, and launch drugs with better curative effects and fewer side effects, so as to improve the condition for patients and gain a larger market share.
Get the Complete Sample, Please Click: https://www.globalmarketmonitor.com/reports/762647-eosinophilic-esophagitis-drug-market-report.htmlWe provide more professional and intelligent market reports to complement your business decisions.
Chinese